Moghimi Sarani E, Shariati S, Askari P, Tavakkol R, Alemzadeh E, Razeghian Jahromi L et al . A Comparative Study: Aripiprazole versus Olanzapine in Treatment of Amphetamine-Induced Psychosis. Journal title 2023; 2 (2) :14-20
URL:
http://jrhms.thums.ac.ir/article-1-75-en.html
Department of Clinical Pharmacy, School of Pharmacy, Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran Clinical Research Development Unit, Imam Reza Hospital, Birjand University of Medical Sciences, Birjand, Iran , motahare_mahi@yahoo.com
Abstract: (6 Views)
Amphetamines are commonly used for attention deficit hyperactivity disorder and sleep disorders, but their overdose can be a serious problem. This study aimed to evaluate and compare the therapeutic effects of aripiprazole and olanzapine in reducing psychotic symptoms in patients experiencing amphetamine-induced psychosis. In this comparative study, 48 patients were evaluated in two groups, with one group receiving olanzapine and the other receiving aripiprazole. The PANSS questionnaire was used to assess patients' psychosis before starting the medication and on the seventh and fourteenth days of treatment. Analytical data were analyzed using KolmogorovSmirnov tests to measure normality, independent t-tests or Mann-Whitney tests, Pearson or Spearman correlations, and Chi-square tests. The results showed that both aripiprazole and olanzapine were effective in reducing positive symptoms and overall psychiatric symptoms in patients with amphetamine-induced psychosis. However, aripiprazole had fewer side effects compared to olanzapine. These findings suggest that aripiprazole may be a good alternative to olanzapine in the treatment of amphetamine-induced psychosis, potentially reducing mortality and morbidity associated with olanzapine use.
Type of Study:
Research |
Subject:
Special Received: 2024/12/23 | Accepted: 2025/03/16 | Published: 2025/07/8